Tarius SAC Tracker®


Results Wire: US FDA Advisory Committee Votes in Favor of Teva’s Reslizumab for Eosinophilic Asthma in Adults and Against Its Use in Adolescents – DEC 9, 2015 (PADAC)

The SAC Tracker report for this meeting is only available for SAC Tracker Premium subscribers.

The SAC Tracker reports are available for FREE on this site until 10 days after the meeting is held. 

To obtain unlimited access to SAC Tracker meeting reports back to 2010 and onwards, including the committee members' voting history, you must subscribe to the SAC Tracker Premium service.

Read more and subscribe here.

METADATA: Sponsor: Teva Pharmaceutical Industries, Ltd. Drug Name: reslizumab Drug Class: interleukin-5 inhibitor Indication: eosinophilic asthma